Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NICH is finally ready to produce and start bottling with Alamo Distillery.
After extensive interviews with multiple nationwide distillery companies, we have finalized a partnership that will produce and bottle Tover Brands through Nitches. $NICH
— Nitches (@nitchescorp) February 23, 2024
We are happy and confident with the quality of Alamo Distillery Co, in San Antonio, TX.
“Noel Burns, we… pic.twitter.com/8tLLEiyR6s
$NICH - Successful meetings have transpired regarding the Nitches / Tover Project.
Successful meetings have transpired regarding the Nitches / Tover Project. 🥂Our media team is putting together formal updates. 🦾Stay tuned for more refined and updated content between today and tomorrow. Until then, please reference the image attached. 😊 $NICH. #Liquor… pic.twitter.com/h8183KDMEv
— Nitches (@nitchescorp) February 22, 2024
$CBDW Huge bounce and run coming. Hope folks paying attention https://schrts.co/pyBvQjKA
$CAUD Collective Audience Appoints Former Ogilvy and WPP Executive, Christopher Andrews, as COO https://finance.yahoo.com/news/collective-audience-appoints-former-ogilvy-133100672.html
$CAUD are a collaborative collective that believes in the power of collective intelligence, and that we are stronger as a group than as individuals. Our superpower is a relentless drive to innovate. The most fruitful collaborations are those where we walk away having learned something new. We are curious, passionate, proactive problem-solvers. We partner with forward-thinking inspiring brands, agencies, and publishers. https://collectiveaudience.co/about/
$LMLLF News Out! PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
https://finance.yahoo.com/news/pharmadrugs-sairiyo-successfully-demonstrates-ability-132500425.html
$AGBA hearing pending press.
$AGBA hearing pending press.
— SheepWolf 💫 (@realsheepwolf) February 13, 2024
Hope you're in position.
•Shares are tight 55.5M of the 58 O/S are held tightly by Tag Holdings (Richard Tsai) and they have never sold a single share.@agbagroup$SYRA $DBGI $OMH $ARBB $FAMI $BDRX $CHSN $WBUY $ILAG $FAMI $BMR $JBLU $LTRY $BCYC pic.twitter.com/6FVrSDNmg7
$AGBA Group’s commission rates from product providers vary by product type, with insurance products averaging around 50-60% of the Annualized New Premium.
$AGBA Group’s commission rates from product providers vary by product type, with insurance products averaging around 50-60% of the Annualized New Premium. Financial advisors are paid approximately 70% of the commissions AGBA Group receives for typical insurance products, with the… pic.twitter.com/n3dVCylQOX
— AGBA (@agbagroup) January 16, 2024
$CAUD - MEET ADVISOR COLLECTIVE MEMBER DAVID KOHL CEO OF TRUSTX https://reddit.com/r/stockstobuytoday/comments/1apyk2s/caud_meet_advisor_collective_member_david_kohl/
$CAUD Chart setting up for the big move https://schrts.co/rWYNCBqs
$CAUD INTRODUCING BEOP GENERATIVE AI CONTENT THATS REVOLUTIONIZING CONVERSATIONAL ADVERTISING CREATIVITY https://collectiveaudience.co/introducing-beop-generative-ai-content-thats-revolutionizing-conversational-advertising-creativity/
$CBDW is excited to announce the launch of an innovative marketing campaign in collaboration with its latest ISO partner, Cannasite. https://finance.yahoo.com/news/1606-corp-launches-2nd-major-133000255.html
$CBDW 1606 Corp. Launches 2nd Major Marketing Campaign With ISO Partner Cannasite https://finance.yahoo.com/news/1606-corp-launches-2nd-major-133000255.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance
$AVRW, with its high value assets including 15 patents and the increasingly successful Seratopical Revolution skin care product line, is very undervalued at current trading levels. The details are all well covered in the recent feature article below. AVRW is now set up to have a record sales and revenue growth year in 2024 based on all the positive groundwork that was laid in the past months.
$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter
From this article:
– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
– Company Currently Holds 15 Patents.
– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.
– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.
– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.
– Q3 Net Revenue Increased Sequentially from Q2 2023.
– Sales Expected to Increase Significantly During Q4 and Into 2024.
– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.
– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.
– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns.
1606 Corp $CBDW has unveiled a strategic plan aimed at catapulting AI Chatbot revenue through (3) fundamental pillars of growth:
1606 Corp $CBDW has unveiled a strategic plan aimed at catapulting AI Chatbot revenue through (3) fundamental pillars of growth:
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 7, 2024
1. ISO partnerships
2. Continued software development
3. Robust internal sales efforts.
This article delves into these strategies, underscoring… pic.twitter.com/rTc08ucmTC
1606 Corp $CBDW has unveiled a strategic plan aimed at catapulting AI Chatbot revenue through (3) fundamental pillars of growth:
1606 Corp $CBDW has unveiled a strategic plan aimed at catapulting AI Chatbot revenue through (3) fundamental pillars of growth:
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 7, 2024
1. ISO partnerships
2. Continued software development
3. Robust internal sales efforts.
This article delves into these strategies, underscoring… pic.twitter.com/rTc08ucmTC
$NICH @nitchescorp is launching this strategic initiative to focus on providing competitive pricing for our manufacturing and production clients in North America and bridge the gap internationally. https://finance.yahoo.com/news/nitches-announces-establishment-overseas-representative-141000881.html
$CBDW Following the remarkable success of our December marketing initiative with Cool Blue Distribution, targeting CBD merchants, we enter this new campaign with high expectations and enthusiasm. The previous campaign not only demonstrated the robust demand for ChatCBDW but also underscored the effectiveness of our marketing strategies in promoting AI chatbot solutions. https://finance.yahoo.com/news/1606-corp-launches-2nd-major-133000255.html
$TMGI and its affiliate Simply Whim, via its licensor Global Holdings Network, is expected to enter into a coexistence agreement for the WHIM trademark with one of the largest beauty brands in the world. https://finance.yahoo.com/news/marquie-group-subsidiary-negotiating-whim-130000218.html
Major News Alert: BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX: $BCT) Breaking Ground in Prostate Cancer: Major Milestone with BriaCell’s Off-The-Shelf Personalized Cellular Cancer Vaccines
https://www.globenewswire.com/news-release/2024/02/06/2824344/0/en/Breaking-Ground-in-Prostate-Cancer-BriaCell-Announces-Lead-Prostate-Cancer-Candidate-Bria-Pros-Initiates-GMP-Manufac
Whether you're into tech or cannabis stocks, $CBDW is definitely one to add and keep on your watchlist.
The Future of Online Shopping: $CBDW 1606's AI-Enabled Retail Chat Bots
$CBDW is pleased to announce its Chairman and CEO, Greg Lambrecht has issued a letter to shareholders. https://cbdw.ai/1606-corp-launches-an-era-of-exceptional-growth-of-cbdw-ai-for-e-commerce/
$ARQ (OTC Pink: $ARBTF) Argo Gold's CEO Judy Baker Unveils Oil Sector Success: Thriving Production, Revenue, and 2024 Plans
$CBDW Next week is a huge week. We have updates coming out on our first big marketing campaign with CannaSite, excited...
What a week! We want to close out the week with a big #Thankyou to our Shareholders & investors, go $CBDW!
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 2, 2024
Next week is a huge week. We have updates coming out on our first big marketing campaign with CannaSite, excited...
We also have a big surprise for our #Sharholders… pic.twitter.com/Bt0xbH6FIi
$RWGI News: Rodedawg Intl. Ind, Inc. (OTC: RWGI) Acquires and Initiates New California Cannabis Distributor License
COSTA MESA, CA , Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rodedawg International Industries, Inc. (OTC: RWGI) proudly announces the Company, through our wholly owned subsidiary, Parabola Mgmt. LLC, has acquired a new California cannabis distributor license in Coachella, California. Chris Swartz, CEO, states “We are proud to inform our shareholders that since the completion of the acquisition of Parabola Mgmt., LLC we have already started the acquisition and expansion of our cannabis license portfolio. We are especially proud to make this announcement as this is a first quarter 2024 milestone that has happened within the timeline of the Company roadmap. As we had previously stated, the acquisition of Parabola Mgmt. LLC included options to purchase additional licenses, we have moved quickly to complete the first purchase and we will continue moving quickly toward expanding the revenues of the Company. We are confident that our strategically planned acquisitions and merger strategy for 2024 will increase 2024 revenues to meeting and potentially exceeding our stated goal of 7 million annually”.
Mr. Swartz concludes, This is one of the many regular updates our shareholders can expect as we complete our 2024 roadmap milestones during this 1st Quarter 2024 that will lead to the significant increases to revenue growth. Once again, we continue to thank our loyal shareholders for their ongoing support as we create Rodedawg to becoming an industry leader in the licensed cannabis market.”
About Rodedawg International Industries, Inc.
Rodedawg International Industries, Inc. (OTC: RWGI) is focused on providing management services, acquisitions and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries.
Please note the company Twitter address is https://twitter.com/RWGImerger for regular updates.
About Budding Horizon, LLC
Budding Horizon, LLC is a California Limited Liability Company with offices in Orange County, California. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://buddinghorizon.com/
About Brother Buds™
Brother Buds is a cannabis delivery service based in Costa Mesa, California. During the month of July 2023, the Rodedawg will operate Brother Buds under a non-storefront cannabis delivery license. The cannabis delivery service will focus on Los Angeles County, Orange County, and norther San Diego County in the demographic area of 23.86 million in 2019. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://BrotherBuds.com
Make sure to follow us at https://twitter.com/BrotherBudsOC
Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Rodedawg International Industries, Inc.
CONTACT: Contact Information: Rodedawg International Industries, Inc. 1-800-793-0355 ir@buddinghorizon.com
Is $CBDW The Next $NICE?
https://cbdw.ai/is-cbdw-the-next-nice/
$CBDW - Looking Ahead: A Vision for 2024 and Beyond
As we progress into 2024, our focus remains steadfast on innovation, quality, and customer satisfaction as we plan to release V2 of ChatCBDW in early Summer 2024. https://cbdw.ai/1606-corp-launches-an-era-of-exceptional-growth-of-cbdw-ai-for-e-commerce/
$MDAI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView system. DeepView is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
$CBDW 1606 Corp’s AI Chatbot Generates Immediate Revenue Growth from New ISO Partnership https://cbdw.ai/news/1606-corps-ai-chatbot-generates-immediate-revenue-growth-from-new-iso-partnership/
$MDAI announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. https://www.spectral-ai.com/press-releases/spectral-ai-begins-enrollment-in-pivotal-study-to-validate-deepview-ai-for-burn-injuries/
$MDAI NEWS IS OUT Spectral Submits Application for UKCA Mark Classification https://stockhouse.com/companies/bullboard/mdai/spectral-ai-inc?postid=35850620
BreakingNews: 1606 Corp.'s $CBDW CEO Interviewed by RedChip Small Stocks, Big Money™ Show regarding AI https://finance.yahoo.com/news/1606-corp-ceo-interviewed-redchip-133000578.html
#Nasdaq $MDAI on High Alert!!!
#MDAI - Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries https://finance.yahoo.com/news/spectral-ai-begins-enrollment-pivotal-130000690.html
#stockstowatch #investors #stocks #traders #stockstobuy
$NICH is thrilled to announce the newest addition to the advisory board of Tover Spirits, a pioneering force in the spirits industry. Mr. Nikola Cvetkovic, renowned for his impactful work at Flaviar.com, has joined Tover Spirits to lend his strategic insights and expertise in launching successful online campaigns and distribution. https://finance.yahoo.com/news/nitches-welcomes-industry-expert-nikola-131500426.html
$CBDW New Blog is out!! Despite Corporate Cost-Cutting, CEOs Are All In On Investing In Generative AI https://cbdw.ai/despite-corporate-cost-cutting-ceos-are-all-in-on-investing-in-generative-ai/
$NXGB Announces that its brand, Mad House Supps, has now produced its product in Australia under license and is ready to sell. https://finance.yahoo.com/news/nxgen-brands-inc-announces-australian-123000570.html
$CBDW 1606 Corp's Partnership with Cannasite Sparks Rapid Revenue Growth for CBDW's AI-Driven Chatbot
Summary of Bionomics (NASDAQ: $BNOX) 2023 Review and 2024 Plans, Potential Catalysts with Timeframes
A Must-Read Report for Biotech Investors and Traders News Source Subscribers…
Positive Developments in 2023:
Phase 2b Data for BNC210 in PTSD: Bionomics announced positive results from the Phase 2b ATTUNE trial in PTSD, showing a reduction in total symptom severity and improvements in multiple symptom clusters. A discussion with the FDA about these results is anticipated in Q2 2024.
End of Phase 2b Meeting for BNC210 in SAD: Following the Phase 2b PREVAIL study, Bionomics had a successful meeting with the FDA, setting the stage for a registrational study in Social Anxiety Disorder (SAD).
Strategic Partnerships: The company is engaged in discussions for potential strategic partnerships for multiple pipeline assetsand is exploring options to advance clinical development plans for BNC210 in both PTSD and SAD.
Key Highlights and Milestones:
BNC210's Role in CNS Disorders: BNC210, a first-in-class a7 nicotinic receptor modulator, showed promise in treating PTSD and SAD. It could become the first "as-needed" non-sedating, non-habit-forming anxiolytic for SAD.
Alzheimer's and Cognitive Impairment: In partnership with MSD, Bionomics is developing a7 PAMs for cognitive disorders like Alzheimer's disease, with two clinical candidates in late Phase 1 development.
Corporate Developments: Bionomics expanded its U.S.-based team, delisted from the Australian Stock Exchange, efficiently allocated capital, and continued strengthening its intellectual property portfolio.
Financial Position: The company has no outstanding debt, convertible securities, or warrants and maintains support from institutional investors.
2024 Outlook and Anticipated Milestones:
Potential Catalysts
Phase 3 Study in SAD: Bionomics plans to initiate the first Phase 3 study of BNC210 in patients with SAD.
Discussions with FDA on PTSD Study: The company anticipates discussing a late-stage study of BNC210 in PTSD with the FDA, with an update expected by the end of Q2 2024.
Breakthrough Therapy Designation: Bionomics is exploring a request for Breakthrough Therapy designation in PTSD in Q2 2024.
Strategic Partnerships: The company aims to establish strategic partnerships for BNC210.
Conclusions from this corporate update:
Bionomics achieved significant milestones in 2023, particularly with the positive results of BNC210 in PTSD and SAD. Looking ahead to 2024, the company is poised for further growth with strategic plans, including initiating Phase 3 studies, pursuing regulatory discussions, and exploring partnerships. Developing innovative treatments for CNS disorders with high unmet medical needs (Large Markets!)
Source article: Original and full company update
Bionomics (BNOX) Strategic partnership with Merck & Co, Inc
The partnership with Merck & Co. on a7 PAMs, with a potential value of $500 million in milestones plus royalties, exemplifies the high-stakes nature of CNS drug development and the significant revenue potential for successful therapies.
Share Statistics
Current Price a/o the close 01/24/2024: 0.99/Share
52-Week Performance:
52 Week High: $7.71
52 Week Low: $0.93
Moving Averages:
50-Day Moving Average: $1.41
200-Day Moving Average: $2.09
Trading Volume:
Average Volume (3 months): 230.33k shares
Average Volume (10 days): 288.59k shares
Share Statistics:
Shares Outstanding: 10.26 million
Float: 8.81 million shares
Percentage Held by Institutions: 32.25%
Sources: Yahoo finance and dilution tracker
Summary
Bionomics (NASDAQ: BNOX) - FDA Announcements and Additional Potential Catalysts with Timeframes
Background:
Bionomics Limited, a clinical-stage biotechnology company, has made significant progress with its lead asset BNC210, aimed at treating Social Anxiety Disorder (SAD). Following a successful End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA) in September 2023, the company is poised to advance BNC210 into Phase 3 registrational studies.
Key FDA Meeting Outcomes:
Agreement on Phase 3 Clinical Program: Bionomics and the FDA have agreed on conducting two randomized, placebo-controlled studies with a single administration of BNC210 during a public speaking task.
Primary Efficacy Endpoint: The Subjective Units of Distress Scale (SUDS) measured during a public speaking challenge will be the primary efficacy endpoint.
Doses for Phase 3 Studies: Specific doses of BNC210 to be studied in Phase 3 have been agreed upon.
Sample Size and Design Elements: The company has aligned with the FDA on the sample size assumptions based on the PREVAIL findings and the design of the open-label safety study required for the New Drug Application (NDA).
Safety Database Size: An agreement on the size of the safety database to support the NDA has been reached.
Nonclinical Toxicology Studies: Requirements for nonclinical toxicology studies needed for the NDA have been established.
Anticipated Timeframes and Potential Catalysts
Initiation of Phase 3 Program: Bionomics plans to begin the Phase 3 program in Q1 2024. This marks a significant milestone and potential catalyst for the company as it moves closer to potential commercialization.
Progress of Phase 3 Studies: The commencement and progress of the Phase 3 studies throughout 2024 will be crucial for Bionomics. Positive interim results or updates could serve as catalysts for investor interest and stock movement.
Strategic Partnerships: Potential partnerships or collaborations related to BNC210, especially in the wake of positive Phase 2 results, could emerge as additional catalysts.
Regulatory Milestones: Any subsequent positive interactions or feedback from the FDA, including potential breakthrough therapy designations or priority reviews, would be significant for the company's trajectory.
Expansion in Other Indications: Given BNC210's potential in multiple anxiety disorders, developments in expanding its application to other related CNS disorders could provide further upside.
Conclusion
Bionomics is positioned for a pivotal year in 2024, with the advancement of BNC210 into Phase 3 studies for SAD being a key focus. The alignment with FDA on critical aspects of the Phase 3 program underscores the company's commitment to addressing the unmet needs in the treatment of SAD. The initiation of these studies, along with potential regulatory and strategic milestones, are poised to serve as significant catalysts for Bionomics in the near future.
Daily Chart
A screenshot of a graph
Description automatically generated
Chart source: Finviz
Stay tuned throughout 2024 for future updates on BNOX.
Full report and disclosures: https://broadstreetalerts.com/wp-content/uploads/2024/01/BNOX-Analysis-Catalysts-01-25-2024-BSA-final.pdf
The Team
$SHMN: TWO cGMP FDA Full Service [Labeling, Packaging & Manufacturing] facilities...
in operation.
1. Company recently acquired a PATENT PORTFOLIO in Gene-Editing [ABBIE],
2. Appointed an Eminent CARDIOLOGIST to help productize the above.
3. New COO, New V.P. of QA [FDA Veteran]
4. Rx & Generics being manufactured since Q3-Q4 of 2023 [Expecting great Annual rpt for 2023]
High Probability of being a PENNYLAND & more Ticker!
$NICH is thrilled to announce the newest addition to the advisory board of Tover Spirits, a pioneering force in the spirits industry. https://finance.yahoo.com/news/nitches-welcomes-industry-expert-nikola-131500426.html
#BreakingNews: $TMGI The Marquie Group Subsidiary Negotiating WHIM Trademark Agreement With Industry Leader https://finance.yahoo.com/news/marquie-group-subsidiary-negotiating-whim-130000218.html
$CBDW 1606 Corp. Signs Second Major ISO Partnership with CannaSite, a Top CBD Web Developer to Market AI Merchandising Chatbots by 1606 https://cbdw.ai/news/1606-corp-signs-second-major-iso-partnership-with-cannasite-a-top-cbd-web-developer-to-market-ai-merchandising-chatbots-by-1606/
Acquisition news - $GIDMF Nexus Announces Option to Acquire Cree East Project in Athabasca Basin https://broadstreetalerts.com/wp-content/uploads/2024/01/GIDMF-Full-Analysis-BSA-01-23-2024.pdf
$CBDW ~ The Dawn of ChatCBDW and What It Means for AI Commerce https://cbdw.ai/how-1606-corp-is-leading-the-ai-merchandising-bot-revolution-validated-by-googles-latest-move/
#CBDW THE BEST AI STOCK TO BUY 2024 $CBDW https://www.reddit.com/r/10xPennyStocks/comments/19cz2j5/cbdw_the_best_ai_stock_to_buy_2024_cbdw/
$CBDW This strategic partnership aims to leverage CannaSite's robust client base and industry influence to expand the reach and impact of 1606 Corp.'s innovative chatbot solutions. https://finance.yahoo.com/news/1606-corp-signs-second-major-130000797.html
$CBDW AI Tech Stocks for 2024 | Top Stock News Today | 1606 Corp | CBDW
Followers
|
945
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
30325
|
Created
|
06/17/11
|
Type
|
Free
|
Moderator ~ Blue ~ | |||
Assistants doogdilinger balamidas MOMO vantillian CHIEF-RISES-ABOVE |
Posts Today
|
0
|
Posts (Total)
|
30325
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |